News | June 05, 2024
AstraZeneca completes acquisition of Fusion Pharmaceuticals
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
With this, for all our USFDA facilities, EIRs are in place
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Subscribe To Our Newsletter & Stay Updated
